Oncology Development ExpertiseThe team's established record in oncology drug development may facilitate discussions around outside development candidates in that category.

Strategic ReviewEPIX is engaging in a strategic review to identify external opportunities to maximize shareholder value, including but not limited to in-licensing external assets and reverse mergers.

Bears Say

Clinical TrialsAll remaining clinical studies involving masofaniten, including combinations with other drugs and investigator-sponsored trials, are being discontinued.

Drug DevelopmentEPIX will discontinue all masofaniten development after a futility analysis showed it failed to meet the target efficacy in the Phase 2 enzalutamide combo study.

Financial OutlookBased on projected year-end cash, the price target is being lowered significantly from $15 to $2.

---

Financials

Annual

Income Statement >

Ownership Overview

2.17% Insiders

0.06% Mutual Funds

0.06% Other Institutional Investors

97.60% Public Companies and Individual Investors

Detailed Ownership Overview >

Risk Analysis

Main Risk Category

Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Detailed Risk Analysis >

EPIX FAQ

What was ESSA Pharma Inc.’s price range in the past 12 months?

ESSA Pharma Inc. lowest stock price was $1.40 and its highest was $11.67 in the past 12 months.

What is ESSA Pharma Inc.’s market cap?

ESSA Pharma Inc.’s market cap is $77.68M.

When is ESSA Pharma Inc.’s upcoming earnings report date?

ESSA Pharma Inc.’s upcoming earnings report date is Feb 06, 2025 which is in 15 days.

How were ESSA Pharma Inc.’s earnings last quarter?

ESSA Pharma Inc. released its earnings results on Dec 17, 2024. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.188 by $0.048.

Is ESSA Pharma Inc. overvalued?

According to Wall Street analysts ESSA Pharma Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ESSA Pharma Inc. pay dividends?

ESSA Pharma Inc. does not currently pay dividends.

What is ESSA Pharma Inc.’s EPS estimate?

ESSA Pharma Inc.’s EPS estimate is -0.18.

How many shares outstanding does ESSA Pharma Inc. have?

ESSA Pharma Inc. has 44,388,550 shares outstanding.

What happened to ESSA Pharma Inc.’s price movement after its last earnings report?

ESSA Pharma Inc. reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.188. Following the earnings report the stock price went up 0.613%.

Which hedge fund is a major shareholder of ESSA Pharma Inc.?

Currently, no hedge funds are holding shares in EPIX

---

ESSA Pharma Stock Smart Score

Unlock Smart Score

Fundamentals

Return on Equity

-21.12%

Trailing 12-Months

Asset Growth

-14.09%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ESSA Pharma Inc.

ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

---